公司新闻稿: Arrowhead将出席即将举行的科学会议

StephenW

Arrowhead to Present at Upcoming Scientific Conferences



PASADENA, Calif. - June 13, 2013 - Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that the company will present data on the Dynamic PolyConjugate™ (DPC) siRNA delivery system and the ARC-520 hepatitis B drug candidate at three upcoming scientific conferences.

Scheduled conference presentations in June include the following:
The 18th Annual Meeting of the RNA Society - Davos, Switzerland, June 14, 2013

A workshop presentation titled, "Development of Dynamic Polyconjugates for tissue-targeted delivery of siRNA," will be presented by Christine Wooddell, Ph.D., Senior Scientist;

4th RNAi Research & Therapeutics Conference - San Francisco, CA, USA, June 21, 2013

A featured presentation titled, "DPC Technology for siRNA Delivery: Moving from Platform to Pipeline," will be presented by David Lewis, Ph.D., Vice President, Biology;

The European CLINAM and ETPN Summit, Clinical Nanomedicine and Targeted Medicine - Basel, Switzerland, June 26, 2013

An oral presentation titled, "A Novel Hepatitis B Treatment with RNAi," will be presented by Christopher Anzalone, Ph.D., President and CEO.

About Arrowhead Research Corporation



Arrowhead Research Corporation is a clinical stage targeted therapeutics company with development programs in oncology, obesity, and chronic hepatitis B virus infection.  The company is leveraging its platform technologies to design and develop peptide-drug conjugates (PDCs) that specifically home to cell types of interest while sparing off-target tissues, create targeted drugs based on the gene silencing RNA interference (RNAi) mechanism, and work with partners to create improved versions of traditional small molecule drugs.



For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to [email protected]

StephenW

箭头将出席即将举行的科学会议



加利福尼亚州帕萨迪纳 -  6月13日，2013  - 箭头研究公司（NASDAQ：ARWR），靶向治疗公司今天宣布，该公司将目前的数据动态PolyConjugate™（DPC）siRNA传递系统，ARC-520的B型肝炎三个即将举行的科学会议的候选药物。

预定在6月会议上介绍包括以下内容：
的RNA学会第18届年会 - 达沃斯，瑞士2013年6月14

一个研讨会的演讲题为“发展动态Polyconjugates组织的siRNA靶向”将提交由Christine Wooddell，博士，高级研究员;

第四届RNAi技术研究及药物治疗学会议 - 旧金山，CA，美国6月21日，2013年

一个有特色的演讲题目，“DPC技术的siRNA传递：移动平台管道，”将提交由大卫·刘易斯博士，副总裁，生物;

的欧洲CLINAM ETPN的首脑会议上，临床纳米医学和靶向药物 - 瑞士巴塞尔，2013年6月26日

口头介绍题为“一种新型乙肝治疗用RNA干扰技术，”将提交由克里斯托弗Anzalone，博士，总裁兼首席执行官。

关于箭头的研究公司



箭头研究公司是一个有针对性的治疗公司在肿瘤学的发展计划，肥胖，慢性乙肝病毒感染的临床分期。该公司利用其平台技术设计和开发多肽偶联药物（PDC）的特别感兴趣的细胞类型，同时保留脱靶组织，建立基于基因沉默的RNA干扰（RNAi）机制，有针对性的药物和工作与合作伙伴共同创造传统的小分子药物的改进版本。



欲了解更多信息，请访问的http://www.arrowheadresearch.com，或跟随我们Twitter上@ ArrowRes的。要添加到公司的电子邮件列表，直接接收新闻，请发送电子邮件至[email protected]

咬牙硬挺

感谢分享

林伍伍

6-26都过了 去他们的官网看 还是没任何动静